These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 21762647)

  • 21. Effects of angiotensin-converting enzyme inhibitor, angiotensin II receptor antagonist and calcium antagonist on urinary podocytes in patients with IgA nephropathy.
    Nakamura T; Ushiyama C; Suzuki S; Hara M; Shimada N; Sekizuka K; Ebihara I; Koide H
    Am J Nephrol; 2000; 20(5):373-9. PubMed ID: 11092994
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Urinary levels of interleukin-8 (IL-8) and disease activity in patients with IgA nephropathy.
    Huang F; Horikoshi S; Kurusu A; Shibata T; Suzuki S; Funabiki K; Shirato I; Tomino Y
    J Clin Lab Anal; 2001; 15(1):30-4. PubMed ID: 11170231
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Up-regulation of urinary markers predict outcome in IgA nephropathy but their predictive value is influenced by treatment with steroids and azathioprine.
    Stangou M; Papagianni A; Bantis C; Moisiadis D; Kasimatis S; Spartalis M; Pantzaki A; Efstratiadis G; Memmos D
    Clin Nephrol; 2013 Sep; 80(3):203-10. PubMed ID: 23611517
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Corticosteroid Treatment Influences TA-Proteinuria and Renal Survival in IgA Nephropathy.
    Sarcina C; Tinelli C; Ferrario F; Visciano B; Pani A; De Silvestri A; De Simone I; Del Vecchio L; Terraneo V; Furiani S; Santagostino G; Corghi E; Pozzi C
    PLoS One; 2016; 11(7):e0158584. PubMed ID: 27416024
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Baseline proteinuria, urinary osmotic pressure, and renal function as positive predictors of corticosteroids plus cyclophosphamide treatment efficacy in IgA nephropathy.
    Fang J; Li W; Li D; Tan Z
    Chin Med J (Engl); 2014; 127(9):1710-4. PubMed ID: 24791879
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acteoside relieves mesangial cell injury by regulating Th22 cell chemotaxis and proliferation in IgA nephropathy.
    Gan L; Li X; Zhu M; Chen C; Luo H; Zhou Q
    Ren Fail; 2018 Nov; 40(1):364-370. PubMed ID: 29708439
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Daily urinary interleukin-11 excretion correlated with proteinuria in IgA nephropathy and lupus nephritis.
    Chien JW; Chen WL; Tsui YG; Lee MC; Lin AY; Lin CY
    Pediatr Nephrol; 2006 Apr; 21(4):490-6. PubMed ID: 16528544
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Urine excretion of a monocytic chemotaxic protein-1 and a transforming growth factor beta1 as an indicator of chronic glomerulonephritis progression].
    Bobkova IN; Chebotareva NV; Kozlovskaia LV; Varshavskiĭ VA; Golitsyna EP
    Ter Arkh; 2006; 78(5):9-14. PubMed ID: 16889042
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The prognostic significance of urinary interleukin 6 in IgA nephropathy.
    Dohi K; Iwano M; Muraguchi A; Horii Y; Hirayama T; Ogawa S; Shiiki H; Hirano T; Kishimoto T; Ishikawa H
    Clin Nephrol; 1991 Jan; 35(1):1-5. PubMed ID: 2007290
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dual renin-angiotensin system blockade plus oral methylprednisone for the treatment of proteinuria in IgA nephropathy.
    Trimarchi H; Muryan A; Young P; Forrester M; Iotti A; Pereyra H; Lombi F; Seminario O; Alonso M; Iotti R
    Medicina (B Aires); 2007; 67(5):445-50. PubMed ID: 18051227
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Urinary IL-6/EGF ratio: a useful prognostic marker for the progression of renal damage in IgA nephropathy.
    Ranieri E; Gesualdo L; Petrarulo F; Schena FP
    Kidney Int; 1996 Dec; 50(6):1990-2001. PubMed ID: 8943482
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Urinary levels of epidermal growth factor, interleukin-6 and monocyte chemoattractant protein-1 may act as predictor markers of renal function outcome in immunoglobulin A nephropathy.
    Stangou M; Alexopoulos E; Papagianni A; Pantzaki A; Bantis C; Dovas S; Economidou D; Leontsini M; Memmos D
    Nephrology (Carlton); 2009 Sep; 14(6):613-20. PubMed ID: 19143943
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Urinary uromodulin excretion predicts progression of chronic kidney disease resulting from IgA nephropathy.
    Zhou J; Chen Y; Liu Y; Shi S; Wang S; Li X; Zhang H; Wang H
    PLoS One; 2013; 8(8):e71023. PubMed ID: 23990922
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Urinary concentration of transforming growth factor-beta-inducible gene-h3(beta ig-h3) in patients with Type 2 diabetes mellitus.
    Cha DR; Kim IS; Kang YS; Han SY; Han KH; Shin C; Ji YH; Kim NH
    Diabet Med; 2005 Jan; 22(1):14-20. PubMed ID: 15606685
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased excretion of urinary transforming growth factor beta 1 in patients with diabetic nephropathy.
    Sato H; Iwano M; Akai Y; Kurioka H; Kubo A; Yamaguchi T; Hirata E; Kanauchi M; Dohi K
    Am J Nephrol; 1998; 18(6):490-4. PubMed ID: 9845822
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pioglitazone reduces urinary protein and urinary transforming growth factor-beta excretion in patients with type 2 diabetes and overt nephropathy.
    Katavetin P; Eiam-Ong S; Suwanwalaikorn S
    J Med Assoc Thai; 2006 Feb; 89(2):170-7. PubMed ID: 16579002
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intrarenal cytokine mRNA expression and location in normal and IgA nephropathy tissue: TGF alpha, TGF beta, IGF 1, IL-4 and IL-6.
    Ballardie FW; Gordon MT; Sharpe PT; Darvill AM; Cheng H
    Nephrol Dial Transplant; 1994; 9(11):1545-52. PubMed ID: 7870340
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influence of cytokine gene polymorphisms on IgA nephropathy.
    Bantis C; Heering P; Aker S; Kuhr N; Grabensee B; Ivens K
    Ren Fail; 2008; 30(2):135-40. PubMed ID: 18300111
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Urinary transforming growth factor-beta 1 in various types of nephropathy.
    De Muro P; Faedda R; Fresu P; Masala A; Cigni A; Concas G; Mela MG; Satta A; Carcassi A; Sanna GM; Cherchi GM
    Pharmacol Res; 2004 Mar; 49(3):293-8. PubMed ID: 14726227
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Add-on angiotensin II receptor blockade lowers urinary transforming growth factor-beta levels.
    Agarwal R; Siva S; Dunn SR; Sharma K
    Am J Kidney Dis; 2002 Mar; 39(3):486-92. PubMed ID: 11877567
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.